“The prospective randomized trial evaluating the efficacy of the mitomycin C and cisplatin regimen (MP) versus standard first-line chemotherapy in patients with advanced BRCA1/2-associated ovarian cancer (NCT04747717)”, Вопр. онкол., vol. 68, no. 5, pp. 628–638, Oct. 2022, doi: 10.37469/0507-3758-2022-68-5-628-638.